INSERM, U1138, Team Cancer, Immune Control, and Escape, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Paris, France; Université Paris Descartes-Paris 5, Paris, France; Université Denis Diderot-Paris 7, Paris, France; Service de Pathologie, Paris, France.
Hôpitaux Universitaire Paris Centre, AP-HP, Service de Chirurgie Thoracique, Paris, France.
Chest. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499.
Histologic classification of lung adenocarcinoma subtype has a prognostic value in most studies. However, lung adenocarcinoma characteristics differ across countries. Here, we aimed at validating the prognostic value of this classification in a large French series of lung adenocarcinoma.
We reviewed 407 consecutive lung adenocarcinomas operated on between 2001 and 2005 and reclassified them according to the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and subsequently graded them into low, intermediate, and high grade. We analyzed the relevance of this classification according to clinical, pathologic, and molecular analysis.
Patients (median age, 61 years; 288 men) underwent lobectomy (n = 378) or pneumonectomy (n = 29). Patients' overall survival at 5 and 10 years was 53.2% and 32.6%, respectively. Union for International Cancer Control stage distribution was 189 stage I, 104 stage II, 107 stage III, and seven stage IV. Low-grade tumor was found in one patient, intermediate grade in 275 patients, and high grade in 131 patients. KRAS and EGFR mutations were detected in 34% and 9.6%, respectively. Histologic grade was significantly correlated with extent of resection (P = .01), thyroid transcriptional factor-1 expression (P = .00000001), vascular emboli (P = .03), and EGFR mutations (P = .01). Mucinous adenocarcinomas were associated with KRAS mutations (P = .003). At univariate analysis, age, extent of resection, histologic grade, pleural invasion, vascular emboli, pathologic T and N, and stage were predictive of survival. At multivariate analysis, age (P = .0001), histologic grade (P = .03), and stage (P = .000003) were independent prognostic factors.
IASLC/ATS/ERS classification of lung adenocarcinomas predicts survival in French population. Histologic grade correlates with clinical, pathologic and molecular parameters suggesting different oncogenic pathways.
在大多数研究中,肺腺癌亚型的组织学分类具有预后价值。然而,肺腺癌的特征因国家而异。在此,我们旨在验证该分类在法国大型肺腺癌系列中的预后价值。
我们回顾了 2001 年至 2005 年间连续进行的 407 例肺腺癌手术,并根据国际肺癌研究协会(IASLC)/美国胸科学会(ATS)/欧洲呼吸学会(ERS)分类对其进行重新分类,并随后将其分为低、中、高级。我们根据临床、病理和分子分析分析了这种分类的相关性。
患者(中位年龄 61 岁;288 名男性)行肺叶切除术(n=378)或全肺切除术(n=29)。患者的 5 年和 10 年总生存率分别为 53.2%和 32.6%。国际抗癌联盟(UICC)分期分布为 189 例 I 期、104 例 II 期、107 例 III 期和 7 例 IV 期。低级别肿瘤见于 1 例患者,中级别肿瘤见于 275 例患者,高级别肿瘤见于 131 例患者。KRAS 和 EGFR 突变分别检出 34%和 9.6%。组织学分级与切除范围显著相关(P=.01),甲状腺转录因子-1 表达(P=0.00000001),血管栓塞(P=.03)和 EGFR 突变(P=.01)。黏液性腺癌与 KRAS 突变相关(P=0.003)。单因素分析显示,年龄、切除范围、组织学分级、胸膜侵犯、血管栓塞、病理 T 和 N 分期以及分期是生存的预测因素。多因素分析显示,年龄(P=0.0001)、组织学分级(P=0.03)和分期(P=0.000003)是独立的预后因素。
IASLC/ATS/ERS 肺腺癌分类可预测法国人群的生存。组织学分级与临床、病理和分子参数相关,提示不同的致癌途径。